Mirdametinib 50 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
Search Results
PP1 2 mg | 99.82%
TargetMol
PP1, a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
More Information Supplier PagePP1
PP1 25 mg | 99.82%
TargetMol
PP1, a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
More Information Supplier PagePP1
Tasisulam 5 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Tasisulam 50 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Tasisulam 25 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Tasisulam 10 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Mirdametinib 5 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
Dalcetrapib 5 mg | 97.99%
TargetMol
Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
More Information Supplier PageDalcetrapib
Dalcetrapib 10 mg | 97.99%
TargetMol
Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
More Information Supplier PageDalcetrapib